Compare OBT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | MRVI |
|---|---|---|
| Founded | 1892 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.6M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | OBT | MRVI |
|---|---|---|
| Price | $35.18 | $3.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $36.00 | $4.57 |
| AVG Volume (30 Days) | 49.3K | ★ 1.1M |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 34.86 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | $119,456,000.00 | ★ $192,435,000.00 |
| Revenue This Year | $9.87 | N/A |
| Revenue Next Year | $7.66 | $10.00 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | ★ 19.42 | N/A |
| 52 Week Low | $20.97 | $1.67 |
| 52 Week High | $35.43 | $5.03 |
| Indicator | OBT | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 80.87 | 35.06 |
| Support Level | $29.33 | $3.07 |
| Resistance Level | $35.07 | $3.51 |
| Average True Range (ATR) | 0.98 | 0.18 |
| MACD | 0.41 | -0.08 |
| Stochastic Oscillator | 92.35 | 6.06 |
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.